Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $67.76 USD
Change Today -0.52 / -0.76%
Volume 1.3M
STJ On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (STJ) Snapshot

Open
$67.70
Previous Close
$68.28
Day High
$67.99
Day Low
$67.23
52 Week High
07/7/14 - $71.90
52 Week Low
10/16/14 - $54.80
Market Cap
19.0B
Average Volume 10 Days
1.5M
EPS TTM
$3.88
Shares Outstanding
280.1M
EX-Date
03/27/15
P/E TM
17.4x
Dividend
$1.16
Dividend Yield
1.62%
Current Stock Chart for ST JUDE MEDICAL INC (STJ)

st jude medical inc (STJ) Related Businessweek News

View More BusinessWeek News

st jude medical inc (STJ) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (STJ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (STJ) Key Developments

St. Jude Medical Inc. Proposes Amendments to its Articles of Incorporation and Bylaws

St. Jude Medical Inc. at the Annual meeting of shareholders to be held on May 7, 2015, proposed amendments to Articles of Incorporation and Bylaws to declassify Board of Directors.

St. Jude Medical Inc. Announces New Champion Data Show Significant Improvement in Survival Rates for Heart Failure Patients with Reduced Ejection Fraction

St. Jude Medical Inc. announced a new data analysis from the CHAMPION trial showing that heart failure (HF) patients with reduced ejection fraction on optimal doses of guideline directed medical therapy (GDMT) managed by pulmonary artery (PA) pressure monitoring with the CardioMEMS - HF System had a 57% reduction in mortality and a 43% reduction in HF hospitalizations compared with patients on GDMT managed by the standard of care (SOC). These data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery. The analysis looked at patients with HF and reduced ejection fraction (HFrEF) (when the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body) over an average of 17 months who were on optimal GDMT and compared those managed by PA pressure monitoring with the CardioMEMS HF System to those managed by SOC. The CHAMPION trial retrospective analysis demonstrated that PA pressure monitoring, in addition to GDMT, significantly reduced HF hospitalizations and mortality in patients with reduced ejection fraction. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery (the artery that delivers blood from the heart to the lungs) during a minimally invasive procedure to directly measure PA pressure. Measuring PA pressure allows clinicians to proactively manage treatment for patients with worsening HF before visible symptoms, such as weight and blood pressure changes, occur. The system allows patients to transmit PA pressure data from their homes to their health care providers, who then manage appropriate medication changes to reduce the likelihood of hospitalization and improve survival.

St. Jude to Pay $14.5 Million to Settle Riata Lawsuits

St. Jude Medical Inc. could pay up to $14.5 million to settle claims over its malfunctioning Riata defibrillator wires. Minnesota Public Radio reports on the disclosure by the med-tech company. It stopped selling the Riata leads in 2010 as reports surfaced the wires were decaying early and breaking through insulation. Faulty defibrillator wires can result in shocking users at the wrong times, or failing to operate when the patient's heart stops.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $67.76 USD -0.52

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $18.40 USD +0.24
Olympus Corp ¥4,390 JPY -50.00
Smith & Nephew PLC 1,136 GBp -10.00
Terumo Corp ¥3,145 JPY -65.00
Zimmer Holdings Inc $114.61 USD -0.75
View Industry Companies
 

Industry Analysis

STJ

Industry Average

Valuation STJ Industry Range
Price/Earnings 19.6x
Price/Sales 3.5x
Price/Book 4.6x
Price/Cash Flow 17.4x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.